Home Online Features Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
Hand-out
Press Releases
Johnson & Johnson  
April 26, 2025

Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy

Salamanca Press

Local & Social
Latest news for you
Cattaraugus County Source
ePaper
google_play
app_store
This Week's Ads
Current e-Edition
ePaper
google_play
app_store
Already a subscriber? Click the image to view the latest e-edition.
Don't have a subscription? Click here to see our subscription options.
Mobile App

Download Now

The Salamanca Press mobile app brings you the latest local breaking news, updates, and more. Read the Salamanca Press on your mobile device just as it appears in print.

ePaper
google_play
app_store
Trending Recipes

Help Our Community

Please help local businesses by taking an online survey to help us navigate through these unprecedented times. None of the responses will be shared or used for any other purpose except to better serve our community. The survey is at: www.pulsepoll.com $1,000 is being awarded. Everyone completing the survey will be able to enter a contest to Win as our way of saying, "Thank You" for your time. Thank You!